Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16704277 | 1.00 | DPP4 (0.51) | DPP4OPRM1OPRD1ELANEF2 | |
| SCHEMBL20859176 | 1.00 | DPP4 (0.51) | DPP4OPRM1OPRD1ELANEF2 | |
| SCHEMBL16704276 | 1.00 | DPP4 (0.51) | DPP4OPRM1OPRD1ELANEF2 | |
| SCHEMBL20853459 | 1.00 | DPP4 (0.51) | DPP4OPRM1OPRD1ELANEF2 | |
| Hydrochloric Acid SCHEMBL20853486 | 0.99 | DPP4 (0.51) | DPP4OPRM1OPRD1ELANEF2 | |
| Hydrochloric Acid SCHEMBL16704079 | 0.99 | DPP4 (0.51) | DPP4OPRM1OPRD1ELANEF2 | |
| Hydrochloric Acid SCHEMBL29613732 | 0.99 | DPP4 (0.51) | DPP4OPRM1OPRD1ELANEF2 | |
| Hydrochloric Acid SCHEMBL16704082 | 0.99 | DPP4 (0.51) | DPP4OPRM1OPRD1ELANEF2 | |
| Hydrochloric Acid SCHEMBL18094988 | 0.99 | DPP4 (0.51) | DPP4OPRM1OPRD1ELANEF2 | |
| SCHEMBL18100583 | 0.90 | ELANE (0.45) | DPP4ELANEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| CN-111187202-B | NMDA antagonist prodrugs | 阿斯利康(瑞典)有限公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |